SINT — Sintx Technologies, Inc.

Summary of Amedica Corporation Q3 2017 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $3 million, a decrease of $0.4 million from Q3 2016.
• Silicon Nitride Product Sales: 41% of total sales, down by $0.7 million year-over-year due to loss of surgeons and restructuring impacts.
• Metal Sales: 59% of total sales, increased by $0.2 million compared to the same period in 2016.
• Net Loss: $2.8 million, improved from a $4.3 million loss in Q3 2016, attributed to reduced operating expenses from restructuring.
• Cash Position: $2.8 million as of September 30, 2017.
• Operating Cash Burn: Decreased to $4.4 million for the nine months ended September 30, 2017, down from $5.3 million in 2016.
• Debt: Reduced to approximately $4.6 million from $7 million in December 2016, with plans to pay off loans by early 2018.

2. Strategic Updates and Business Highlights

• Surgeon Users: Increased by 30%, with a 15% rise in sales agents.
• Product Launch: Successful introduction of the Taurus Pedicle Screw System, generating over $1 million in revenue from over 200 surgeries performed.
• R&D Investments: Continued focus on research with 19 peer-reviewed articles and collaborations with institutions like Texas A&M and Clemson University.
• FDA Submission: Filed a 510(k) for the Valeo C+CSC with Lumen spinal implant, aiming to introduce porous silicon nitride technology to the U.S. market.
• International Expansion: Continued focus on U.S. market while exploring opportunities in Europe, Brazil, and Australia.

3. Forward Guidance and Outlook

• Amedica aims to stabilize and grow spine sales, supported by new product launches and increased surgeon adoption.
• Plans to release additional instrument sets to meet demand and drive revenue growth.
• The company remains committed to maintaining fiscal discipline and expects to enter 2018 with minimal debt.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Overall revenue decreased due to loss of surgeon users and price erosion.
• Increased Costs: Cost of revenue rose by 84%, primarily due to higher inventory reserve provisions.
• Competitive Pressures: The company faces challenges in regaining market share lost during restructuring efforts in late 2016.

5. Notable Q&A Insights

• The session did not include a formal Q&A segment, but the CEO encouraged stakeholders to submit questions and suggestions via email for future engagement.

Overall, Amedica Corporation is working towards stabilizing its financial position and enhancing its product offerings while navigating challenges related to revenue decline and competitive pressures.